Health benefits of combined oral contraceptives – a narrative review: The European Journal of Contraception & Reproductive Health Care

Hormonal contraception, especially “Pill” use, has many non-contraceptive advantages related to the reproductive tract, to non-gynecological diseases and a very important and significantly lower risk of endometrial cancer, ovarian cancer and colon cancer.

Since the first oral contraceptive pill “Enovid” entered the market in the USA in May 1960 and became available for women and their partners to prevent unwanted pregnancy, over the years, 12 review papers have been published to focus the attention on these advantages,

Because the last review of the pill advantages appeared in 2015, we decided to update the situation and on 01 March 2024, “The European Journal of Contraception & Reproductive Health Care” has published on line our review paper entitled “Health benefits of combined oral contraceptives – a narrative review” by Herjan J. T. Coelingh Bennink, Femke A. M. van Gennip, Mireille G. F. Gerrits, Jan F. M. Egberts, Kristina Gemzell-Danielsson & Helena Kopp-Kallner.

At present hormonal contraception is under increasing criticism of lay and assumed experts because of exaggerated attention for the side effects that occur indeed, especially a tiny risk of thrombosis and the subjective side effects due to the loss of female testosterone by to suppression of the menstrual cycle, but these disadvantages should be balanced against the multiple huge non-contraceptive advantages of the pill.

To link to this article: https://doi.org/10.1080/13625187.2024.2317295